miR-34: From bench to bedside

Oncotarget

Volumn 5, Issue 4, 2014, Pages 872-881

  Agostini, Massimiliano ^a   Knight, Richard A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cancer; microRNA; miR 34 family; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; MESSENGER RNA 34; MESSENGER RNA 34A; PROTEIN P53; UNCLASSIFIED DRUG; MICRORNA;

ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CELL DEATH; DRUG DESIGN; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; METASTASIS INHIBITION; MOLECULAR CLONING; NONHUMAN; RNA GENE; TISSUE DISTRIBUTION; ANIMAL; GENETICS; METABOLISM; NEOPLASMS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HUMANS; MICRORNAS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897410547     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1825     Document Type: Article

References (100)

1. Stefani G and Slack FJ. Small non-coding RNAs in animal development. Nature reviews Molecular cell biology. 2008; 9(3):219-230.
2. Garzon R, Calin GA and Croce CM. MicroRNAs in Cancer. Annual review of medicine. 2009; 60:167-179.
3. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010; 17(2):193-199.
4. Kinoshita T, Hanazawa T, Nohata N, Kikkawa N, Enokida H, Yoshino H, Yamasaki T, Hidaka H, Nakagawa M, Okamoto Y and Seki N. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget. 2012; 3(11):1386-1400.
5. Lezina L, Purmessur N, Antonov AV, Ivanova T, Karpova E, Krishan K, Ivan M, Aksenova V, Tentler D, Garabadgiu AV, Melino G and Barlev NA. miR-16 and miR-26a target checkpoint kinases Wee1 and Chk1 in response to p53 activation by genotoxic stress. Cell death&disease. 2013; 4:e953.
6. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Muller PA, Dotsch V, Kehrloesser S, Sayan BS, Giaccone G, Lowe SW, Takahashi N, Vandenabeele P, Knight RA, Levine AJ, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A. 2012; 109(38):15312-15317.
7. Ell B and Kang Y. MicroRNAs as regulators of tumor-associated stromal cells. Oncotarget. 2013; 4(12):2166-2167.
8. Hartl M and Grunwald Kadow IC. New roles for "old" microRNAs in nervous system function and disease. Frontiers in molecular neuroscience. 2013; 6:51.
9. Parisi C, Arisi I, D'Ambrosi N, Storti AE, Brandi R, D'Onofrio M and Volonte C. Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell death&disease. 2013; 4:e959.
10. Sano T, Reynolds JP, Jimenez-Mateos EM, Matsushima S, Taki W and Henshall DC. MicroRNA-34a upregulation during seizure-induced neuronal death. Cell death&disease. 2012; 3:e287.
11. Volvert ML, Rogister F, Moonen G, Malgrange B and Nguyen L. MicroRNAs tune cerebral cortical neurogenesis. Cell Death Differ. 2012; 19(10):1573-1581.
12. Meijer HA, Kong YW, Lu WT, Wilczynska A, Spriggs RV, Robinson SW, Godfrey JD, Willis AE and Bushell M. Translational repression and eIF4A2 activity are critical for microRNA-mediated gene regulation. Science. 2013; 340(6128):82-85.
13. Jopling CL, Yi M, Lancaster AM, Lemon SM and Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005; 309(5740):1577-1581.
14. Orom UA, Nielsen FC and Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008; 30(4):460-471.
15. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010; 140(5):652-665.
16. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, Lopes B, Schiff D, Purow B and Abounader R. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009; 69(19):7569-7576.
17. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM and Esteller M. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A. 2008; 105(36):13556-13561.
18. Shen Z, Zhan G, Ye D, Ren Y, Cheng L, Wu Z and Guo J. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Medical oncology. 2012; 29(4):2473-2480.
19. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA and Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature. 2007; 447(7148):1130-1134.
20. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A and Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26(5):745-752.
21. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z and Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007; 26(5):731-743.
22. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G and Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007; 6(13):1586-1593.
23. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR and Fearon ER. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Current biology: CB. 2007; 17(15):1298-1307.
24. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM and Maris JM. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res. 2008; 6(5):735-742.
25. Leucci E, Cocco M, Onnis A, De Falco G, van Cleef P, Bellan C, van Rijk A, Nyagol J, Byakika B, Lazzi S, Tosi P, van Krieken H and Leoncini L. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008; 216(4):440-450.
26. Kong YW, Cannell IG, de Moor CH, Hill K, Garside PG, Hamilton TL, Meijer HA, Dobbyn HC, Stoneley M, Spriggs KA, Willis AE and Bushell M. The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. Proc Natl Acad Sci U S A. 2008; 105(26):8866-8871.
27. Silber J, Jacobsen A, Ozawa T, Harinath G, Pedraza A, Sander C, Holland EC and Huse JT. miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS One. 2012; 7(3):e33844.
28. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J and Khan J. The MYCN oncogene is a direct target of miR-34a. Oncogene. 2008; 27(39):5204-5213.
29. Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, Cha SY, Ryu JK, Yoon D, Fearon ER, Rowe RG, Lee S, Maher CA, Weiss SJ and Yook JI. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. The Journal of cell biology. 2011; 195(3):417-433.
30. Kim NH, Cha YH, Kang SE, Lee Y, Lee I, Cha SY, Ryu JK, Na JM, Park C, Yoon HG, Park GJ, Yook JI and Kim HS. p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells. Cell Cycle. 2013; 12(10):1578-1587.
31. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M and Allgayer H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene. 2011; 30(25):2888-2899.
32. Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, Pertsemlidis A, Gregory PA, Wright JA, Goodall GJ, Flores ER and Kurie JM. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. The Journal of clinical investigation. 2012; 122(9):3170-3183.
33. Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Frontiers in genetics. 2012; 3:120.
34. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
35. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C and Pan H. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell death&disease. 2013; 4:e838.
36. Sotgia F, Martinez-Outschoorn UE and Lisanti MP. Cancer metabolism: new validated targets for drug discovery. Oncotarget. 2013; 4(8):1309-1316.
37. Lau NC, Lim LP, Weinstein EG and Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001; 294(5543):858-862.
38. Yang J, Chen D, He Y, Melendez A, Feng Z, Hong Q, Bai X, Li Q, Cai G, Wang J and Chen X. MiR-34 modulates Caenorhabditis elegans lifespan via repressing the autophagy gene atg9. Age (Dordr). 2013; 35(1):11-22.
39. Henrich KO, Schwab M and Westermann F. 1p36 tumor suppression--a matter of dosage? Cancer Res. 2012; 72(23):6079-6088.
40. Laake K, Odegard A, Andersen TI, Bukholm IK, Karesen R, Nesland JM, Ottestad L, Shiloh Y and Borresen-Dale AL. Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM. Genes Chromosomes Cancer. 1997; 18(3):175-180.
41. Bernard OA and Berger R. Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromosomes Cancer. 1995; 13(2):75-85.
42. Seeliger MA and Moll UM. p73 - constitutively open for business. Cell Death Differ. 2013; 20(8):972-973.
43. Welch C, Chen Y and Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007; 26(34):5017-5022.
44. Agostini M, Tucci P, Killick R, Candi E, Sayan BS, Rivetti di Val Cervo P, Nicotera P, McKeon F, Knight RA, Mak TW and Melino G. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci U S A. 2011; 108(52):21093-21098.
45. Kracikova M, Akiri G, George A, Sachidanandam R and Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ. 2013; 20(4):576-588.
46. Ghawanmeh T, Thunberg U, Castro J, Murray F and Laytragoon-Lewin N. miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment. Oncology. 2011; 81(5-6):330-335.
47. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z and Zheng X. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008; 582(10):1564-1568.
48. Tazawa H, Tsuchiya N, Izumiya M and Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A. 2007; 104(39):15472-15477.
49. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M and Lund AH. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 2010; 17(2):236-245.
50. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z and Zheng X. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008; 582(10):1564-1568.
51. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T and Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008; 377(1):114-119.
52. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D and Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008; 8:266.
53. Brabletz T. MiR-34 and SNAIL: another double-negative feedback loop controlling cellular plasticity/EMT governed by p53. Cell Cycle. 2012; 11(2):215-216.
54. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D and Tang DG. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-215.
55. Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, D'Andrea A, Vidigal JA, Maughan WP, Ogrodowski P and Ventura A. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet. 2012; 8(7):e1002797.
56. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, Zhong Y, Kim SY, Bennett MJ, Chen C, Ozturk A, Hicks GG, Hannon GJ and He L. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol. 2011; 13(11):1353-1360.
57. Bagchi A and Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res. 2008; 68(8):2551-2556.
58. Gao H, Zhao H and Xiang W. Expression level of human miR-34a correlates with glioma grade and prognosis. Journal of neuro-oncology. 2013; 113(2):221-228.
59. Li WB, Ma MW, Dong LJ, Wang F, Chen LX and Li XR. MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme. Cancer biology&therapy. 2011; 12(6):477-483.
60. Nalls D, Tang SN, Rodova M, Srivastava RK and Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One. 2011; 6(8):e24099.
61. Vogt M, Munding J, Gruner M, Liffers ST, Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A and Hermeking H. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 2011; 458(3):313-322.
62. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J and Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008; 7(16):2591-2600.
63. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y and Tokino T. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008; 68(11):4123-4132.
64. Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T and Hermeking H. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer. Clin Cancer Res. 2013; 19(3):710-720.
65. Nguyen LV, Vanner R, Dirks P and Eaves CJ. Cancer stem cells: an evolving concept. Nature reviews Cancer. 2012; 12(2):133-143.
66. Fareh M, Turchi L, Virolle V, Debruyne D, Almairac F, de-la-Forest Divonne S, Paquis P, Preynat-Seauve O, Krause KH, Chneiweiss H and Virolle T. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ. 2012; 19(2):232-244.
67. Liu H, Zhang W, Jia Y, Yu Q, Grau GE, Peng L, Ran Y, Yang Z, Deng H and Lou J. Single-cell clones of liver cancer stem cells have the potential of differentiating into different types of tumor cells. Cell death&disease. 2013; 4:e857.
68. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, Xiang C, Poisson L, de Carvalho AC, Slavin S, Jacoby E, Yalon M, Toren A, Mikkelsen T and Brodie C. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013; 4(5):665-676.
69. Audrito V, Vaisitti T, Rossi D, Gottardi D, D'Arena G, Laurenti L, Gaidano G, Malavasi F and Deaglio S. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res. 2011; 71(13):4473-4483.
70. Yamakuchi M, Ferlito M and Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A. 2008; 105(36):13421-13426.
71. Yamakuchi M and Lowenstein CJ. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle. 2009; 8(5):712-715.
72. Bu P, Chen KY, Chen JH, Wang L, Walters J, Shin YJ, Goerger JP, Sun J, Witherspoon M, Rakhilin N, Li J, Yang H, Milsom J, Lee S, Zipfel W, Jin MM, et al. A microRNA miR-34a-regulated bimodal switch targets notch in colon cancer stem cells. Cell stem cell. 2013; 12(5):602-615.
73. Antonov AV, Knight RA, Melino G, Barlev NA and Tsvetkov PO. MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets. Cell Death Differ. 2013; 20(2):367.
74. Antonov AV. BioProfiling.de: analytical web portal for high-throughput cell biology. Nucleic acids research. 2011; 39(Web Server issue):W323-327.
75. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM and Maris JM. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res. 2008; 6(5):735-742.
76. Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D, Doan NB, Said JW, Black KL and Phillip Koeffler H. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene. 2013; 32(9):1155-1163.
77. Chen QR, Yu LR, Tsang P, Wei JS, Song YK, Cheuk A, Chung JY, Hewitt SM, Veenstra TD and Khan J. Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a. J Proteome Res. 2011; 10(2):479-487.
78. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM and Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010; 107(1):264-269.
79. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H and Nikitin AY. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010; 16(4):1119-1128.
80. Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, Nagashima Y, Kubota Y and Ishiguro H. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget. 2012; 3(11):1455-1471.
81. Visone R, Veronese A, Balatti V and Croce CM. MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget. 2012; 3(2):195-202.
82. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D and Bader AG. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010; 70(14):5923-5930.
83. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT and Maitra A. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Molecular cancer therapeutics. 2011; 10(8):1470-1480.
84. Chen Y, Zhu X, Zhang X, Liu B and Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Molecular therapy: the journal of the American Society of Gene Therapy. 2010; 18(9):1650-1656.
85. Zhao X, Pan F, Holt CM, Lewis AL and Lu JR. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert opinion on drug delivery. 2009; 6(7):673-686.
86. Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Roh S, Hoffmann R, Warscheid B and Hermeking H. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics. 2011; 10(8):M111 010462.
87. Karaayvaz M, Zhai H and Ju J. miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell death&disease. 2013; 4:e659.
88. Yu X, Zhen Y, Yang H, Wang H, Zhou Y, Wang E, Marincola FM, Mai C, Chen Y, Wei H, Song Y, Lyu X, Ye Y, Cai L, Wu Q, Zhao M, et al. Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma. Cell death&disease. 2013; 4:e634.
89. Lin J, Teo S, Lam DH, Jeyaseelan K and Wang S. MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme. Cell death&disease. 2012; 3:e398.
90. Zhao Y, Butler EB and Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell death&disease. 2013; 4:e532.
91. Sarvaiya PJ, Guo D, Ulasov I, Gabikian P and Lesniak MS. Chemokines in tumor progression and metastasis. Oncotarget. 2013; 4(12):2171-2185.
92. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, Kaluza D, Treguer K, Carmona G, Bonauer A, Horrevoets AJ, Didier N, Girmatsion Z, Biliczki P, Ehrlich JR, Katus HA, et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013; 495(7439):107-110.
93. Pigazzi M, Manara E, Baron E and Basso G. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res 2009; 69(6):2471-8
94. Yang S, Li Y, Gao J, Zhang T, Li S, Luo, Chen H, Ding F, Wang X and Liu, Z. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. 2013; 32(36):4294-303.
95. Wu J, Wu G, Lv L, Ren YF, Zhang XJ, Xue YF, Li G, Lu X, Sun Z, and Tang KF MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis. 2012; 33(3):519-28.
96. Kim HR, Roe JS, Lee JE, Hwang IY, Cho EJ and Youn HD A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH. Biochem Biophys Res Commun. 2012; 418(4):682-8.
97. Kim HR, Roe JS, Cho EJ and Youn HD p53 regulates glucose metabolism by miR-34a. Biochem Biophys Res Commun. 2013; 437(2):225-31
98. Lefort K, Brooks Y, Ostano P, Cario-Andre M, Calpini V, Guinea-Viniegra J, Albinger-Hegyi A, Hoetzenecker W, Kolfschoten I, Wagner EF, Werner S, Dotto G P. A miR-34a-SIRT6 axis in the squamous cell differentiation network. EMBO J 2013; 32(16):2248-63
99. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, Kang SE Cha SY Ryu JK, Na JM, Park C, Kim K, Lee S, Gumbiner BM, Yook JI and Weiss SJ. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 2011; 4(197): ra71
100. de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, De Vita G, Carotenuto M, Bello A, Formiggini F, Galeone A, De Rosa G, Virgilio A, Scognamiglio I, Sciro M, Basso G, et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One. 2011;6(9):e24584